AAAAAA
Results: 1-25/68
Authors:
Schoemaker, NE
Frigerio, E
Fraier, D
Schellens, JHM
Rosing, H
Jansen, S
Beijnen, JH
Citation: Ne. Schoemaker et al., High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma, J CHROMAT B, 763(1-2), 2001, pp. 173-183
Authors:
Bardelmeijer, HA
Ouwehand, M
Beijnen, JH
Schellens, JHM
van Tellingen, O
Citation: Ha. Bardelmeijer et al., Determination of cyclosporin A in human and mouse plasma by reversed-phasehigh-performance liquid chromatography, J CHROMAT B, 763(1-2), 2001, pp. 201-206
Authors:
Kemper, EM
Jansen, B
Brouwer, KR
Schellens, JHM
Beijnen, JH
van Tellingen, O
Citation: Em. Kemper et al., Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection, J CHROMAT B, 759(1), 2001, pp. 135-143
Authors:
Malingre, MM
Rosing, H
Koopman, FJ
Schellens, JHM
Beijnen, JH
Citation: Mm. Malingre et al., Performance of the analytical assays of paclitaxel, docetaxel, and cyclosporin a in a routine hospital laboratory setting, J LIQ CHR R, 24(17), 2001, pp. 2697-2717
Authors:
Maliepaard, M
van Gastelen, MA
Tohgo, A
Hausheer, FH
van Waardenburg, RCAM
de Jong, LA
Pluim, D
Beijnen, JH
Schellens, JHM
Citation: M. Maliepaard et al., Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918, CLIN CANC R, 7(4), 2001, pp. 935-941
Authors:
Cocquyt, V
Van Belie, S
Reinhardt, RR
Decramer, MLA
O'Brien, M
Schellens, JHM
Borms, M
Verbeke, L
Van Aelst, F
De Smet, M
Carides, AD
Eldridge, K
Gertz, BJ
Citation: V. Cocquyt et al., Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis, EUR J CANC, 37(7), 2001, pp. 835-842
Authors:
Ravaud, A
Borner, M
Schellens, JHM
Geoffrois, L
Schoffski, BP
Kroon, K
Wanders, J
Hanauske, AR
Fumoleau, P
Citation: A. Ravaud et al., UFT and leucovorin in first-line chemotherapy for patients with metastaticgastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial, EUR J CANC, 37(13), 2001, pp. 1642-1647
Authors:
Sparidans, RW
Rosing, H
Hillebrand, MJX
Lopez-Lazaro, L
Jimeno, JM
Manzanares, I
van Kesteren, C
Cvitkovic, E
van Oosterom, AT
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man, ANTI-CANC D, 12(8), 2001, pp. 653-666
Authors:
Schellens, JHM
Planting, AST
Ma, J
Maliepaard, M
de Vos, A
Dennert, MD
Verweij, J
Citation: Jhm. Schellens et al., Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer, ANTI-CANC D, 12(8), 2001, pp. 667-675
Authors:
Sparidans, RW
Stokvis, E
Jimeno, JM
Lopez-Lazaro, L
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F, ANTI-CANC D, 12(7), 2001, pp. 575-582
Authors:
Schellens, JHM
Dombernowsky, P
Cassidy, J
Epelbaum, R
Dirix, L
Cox, EH
Wanders, J
Calabresi, F
Paridaens, R
Monfardini, S
Wolff, J
Loos, WJ
Verweij, J
Pavlidis, N
Hanauske, AR
Citation: Jhm. Schellens et al., Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9, ANTI-CANC D, 12(7), 2001, pp. 583-590
Authors:
Malingre, MM
Huinink, WWT
Duchin, K
Schellens, JHM
Beijnen, JH
Citation: Mm. Malingre et al., Pharmacokinetics of oral cyclosporin A when co-administered to enhance theoral absorption of paclitaxel, ANTI-CANC D, 12(7), 2001, pp. 591-593
Authors:
Terwogt, JMM
Huinink, WWT
Schellens, JHM
Schot, M
Mandjes, IAM
Zurlo, MG
Rocchetti, M
Rosing, H
Koopman, FJ
Beijnen, JH
Citation: Jmm. Terwogt et al., Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel, ANTI-CANC D, 12(4), 2001, pp. 315-323
Authors:
Malingre, MM
Beijnen, JH
Rosing, H
Koopman, FJ
van Tellingen, O
Duchin, K
Huinink, WWT
Swart, M
Lieverst, J
Schellens, JHM
Citation: Mm. Malingre et al., The effect of different doses of cyclosporin A on the systemic exposure oforally administered paclitaxel, ANTI-CANC D, 12(4), 2001, pp. 351-358
Authors:
Crul, M
de Klerk, GJ
Beijnen, JH
Schellens, JHM
Citation: M. Crul et al., Ras biochemistry and farnesyl transferase inhibitors: a literature survey, ANTI-CANC D, 12(3), 2001, pp. 163-184
Authors:
Crul, M
van den Bongard, HJGD
Tibben, MM
van Tellingen, O
Sava, G
Schellens, JHM
Beijnen, JH
Citation: M. Crul et al., Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry, FRESEN J AN, 369(5), 2001, pp. 442-445
Authors:
Malingre, MM
Richel, DJ
Beijnen, JH
Rosing, H
Koopman, FJ
Huinink, WWTB
Schot, ME
Schellens, JHM
Citation: Mm. Malingre et al., Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel, J CL ONCOL, 19(4), 2001, pp. 1160-1166
Authors:
van den Bongard, HJGD
Mathot, RAA
Boogerd, W
Schornagel, JH
Soesan, M
Schellens, JHM
Beijnen, JH
Citation: Hjgd. Van Den Bongard et al., Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure, CANC CHEMOT, 47(6), 2001, pp. 537-540
Authors:
Malingre, MM
Beijnen, JH
Rosing, H
Koopman, FJ
van Tellingen, O
Duchin, K
Huinink, WWT
Swart, M
Lieverst, J
Schellens, JHM
Citation: Mm. Malingre et al., A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A, CANC CHEMOT, 47(4), 2001, pp. 347-354
Authors:
Kerbusch, T
de Kraker, J
Keizer, HJ
van Putten, JWG
Groen, HJM
Jansen, RLH
Schellens, JHM
Beijnen, JH
Citation: T. Kerbusch et al., Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites, CLIN PHARMA, 40(1), 2001, pp. 41-62
Authors:
Huitema, ADR
Mathot, RAA
Tibben, MM
Schellens, JHM
Rodenhuis, S
Beijnen, JH
Citation: Adr. Huitema et al., Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy, BR J CL PH, 51(1), 2001, pp. 61-70
Authors:
Nuijen, B
Bouma, M
Schellens, JHM
Beijnen, JH
Citation: B. Nuijen et al., Progress in the development of alternative pharmaceutical formulations of taxanes, INV NEW DR, 19(2), 2001, pp. 143-153
Authors:
Malingre, MM
Beijnen, JH
Schellens, JHM
Citation: Mm. Malingre et al., Oral delivery of taxanes, INV NEW DR, 19(2), 2001, pp. 155-162
Authors:
Kerbusch, T
Mathot, RAA
Keizer, HJ
Kaijser, GP
Schellens, JHM
Beijnen, JH
Citation: T. Kerbusch et al., Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites, DRUG META D, 29(7), 2001, pp. 967-975
Authors:
Kerbusch, T
Mathot, RAA
Keizer, HJ
Ouwerkerk, J
Rodenhuis, S
Schellens, JHM
Beijnen, JH
Citation: T. Kerbusch et al., Population pharmacokinetics and exploratory pharmacodynamics of ifosfamideand metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma, EUR J CL PH, 57(6-7), 2001, pp. 467-477